www.fdanews.com/articles/197608-eu-provides-113-million-for-biontechs-covid-19-vaccine-program
EU Provides $113 Million for BioNTech’s COVID-19 Vaccine Program
June 15, 2020
The EU’s lending arm, the European Investment Bank, is making available up to $113 million in financing for BioNTech’s COVID-19 vaccine program.
The European Investment Bank funding will support global development of BNT162, a messenger RNA-based vaccine, and the scaling up of manufacturing capacity in Europe.
Germany-based BioNTech is developing that vaccine candidate in collaboration with Pfizer.